3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine | 607374-09-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine
• 英文别名: 3-(1-ethylimidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine
• CAS: 607374-09-4
• 化学式: C₁₂H₁₂N₆
• mdl: MFCD21568748
• 分子量: 240.267
• InChiKey: SGZHPJLXUXPUIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  82.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以79%的产率得到5-bromo-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine
  参考文献：
  名称：

  WO2006/63167

  摘要：

  公开号：
• 作为产物：
  描述：

  4-乙氨基-3-硝基吡啶 在 palladium on activated charcoal PPA 、 氢气 作用下， 生成 3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine
  参考文献：
  名称：

  (1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors

  摘要：

  A novel series of imidazo[4,5-c]pyridines bearing a 1,2,5-oxadiazol-3-ylamine functionality has been developed. These are potent inhibitors of mitogen and stress-activated protein kinase-1. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.021

文献信息

• [EN] IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES D'IMIDAZOPYRIDINE EN TANT QU'INHIBITEURS DE KINASE
  申请人：GLAXO GROUP LTD

  公开号：WO2003080610A1

  公开（公告）日：2003-10-02

  A compound of the formula: (I) and-physiologically acceptable salts and or N-oxides thereof wherein, X1 is N or CR.3; X2 is N or CR'4; X3 ,is..N or CR5; X4 is N or CR6 with the proviso that at least one but not more than two of X1, X 2, X,3. and X4 represents N. R1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d formula: (II) wherein X5 is a group selected from N or CR7: and X6, is a group selected from O, S or NR8; X7 and X8; which maybe the same or, different is a group selected from N or CR9; ; X9, is a group selected from O, S or NR8 and X10 is N or CR10 ; X11 , X12 and X13 may be the same or different and selected from a group N or CR11 ; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.

  化合物的式子为：（I），其生理上可接受的盐和/或N-氧化物，其中，X1为N或CR.3；X2为N或CR'4；X3为N或CR5；X4为N或CR6，但至少其中一个但不超过两个X1、X2、X3和X4代表N。R1是从a、b、c或d组中选择的5-或6-成员杂环基，式子为：（II），其中X5是从N或CR7选择的基团；X6是从O、S或NR8选择的基团；X7和X8可以相同或不同，是从N或CR9选择的基团；X9是从O、S或NR8选择的基团，X10是N或CR10；X11、X12和X13可以相同或不同，是从N或CR11的基团中选择的；制备它们的过程，包含它们的制药组合物以及它们在医学上的用途。
• Imidazopyridine derivatives as kinase inhibitors
  申请人：Bailey Nicholas

  公开号：US20050197328A1

  公开（公告）日：2005-09-08

  A compound of the formula and physiologically acceptable salts and or N-oxides thereof wherein, X 1 is N or CR 3 ; X 2 is N or CR 4 ; X 3 is N or CR 5 ; X 4 is N or CR 6 . with the proviso that at least one but not more than two of X 1 , X 2 , X 3 and X 4 represents N. R 1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d wherein X 5 is a group selected from N or CR 7 and X 6 is a group selected from O, S or NR 8; X 7 and X 8 which may be the same or different is a group selected from N or CR 9; X 9 is a group selected from O, S or NR 8 and X 10 is N or CR 10; X 11 , X 12 and X 13 may be the same or different and selected from a group N or CR 11 ; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.

  式中化合物及其生理上可接受的盐和/或N-氧化物，其中： X1为N或CR3； X2为N或CR4； X3为N或CR5； X4为N或CR6； 但须满足X1、X2、X3和X4中至少一个但不超过两个为N； R1为从a、b、c或d组中选择的5-或6-成员杂环基，其中X5为N或CR7组，X6为O、S或NR8组； X7和X8可以相同或不同，为N或CR9组； X9为O、S或NR8组，X10为N或CR10组； X11、X12和X13可以相同或不同，为N或CR11组； 本发明还涉及其制备方法、包含它们的制药组合物以及它们在医学上的应用。
• Chemical compounds
  申请人：Alberti John Michael

  公开号：US20060084651A1

  公开（公告）日：2006-04-20

  The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medcicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity.

  本发明涉及氨基嘧啶衍生物、含有该衍生物的组合物和药物以及制备和使用这些化合物、组合物和药物的方法。这种氨基嘧啶衍生物对于治疗与不当酪氨酸和/或丝氨酸/苏氨酸激酶活性有关的疾病是有用的。
• AMINOPYRAZINE DERIVATIVES AND COMPOSITIONS
  申请人：ALBERTI John Michael

  公开号：US20090318472A1

  公开（公告）日：2009-12-24

  The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity.

  本发明涉及氨基吡嗪衍生物、含有这些衍生物的组合物和药物，以及制备和使用这些化合物、组合物和药物的方法。这样的氨基吡嗪衍生物可用于治疗与不适当的酪氨酸和/或丝氨酸/苏氨酸激酶活性相关的疾病。
• 1H-Pyrrolo[2,3-B]Pyridnes
  申请人：Frazee James S.

  公开号：US20090233955A1

  公开（公告）日：2009-09-17

  Derivatives of pyrrolo[2,3-b]pyridine which are useful as SGK-1 kinase inhibitors are described herein. The invention described herein also describes pharmaceutical compositions containing derivatives of pyrrolo[2,3-b]pyridine and methods of using pyrrolo[2,3-b]pyridine derivatives and pharmaceutical compositions thereof in the treatment of diseases mediated by SGK-1.

  本文描述了用作SGK-1激酶抑制剂的吡咯并[2,3-b]吡啶衍生物。本发明还描述了含有吡咯并[2,3-b]吡啶衍生物的制药组合物以及使用吡咯并[2,3-b]吡啶衍生物和其制药组合物治疗由SGK-1介导的疾病的方法。